(3,5-diethylphenyl)methanol | 198623-53-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,5-diethylphenyl)methanol
• CAS: 198623-53-9
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: UPAGPHGQGBPOJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3,5-diethylphenyl)methanol 在 三溴化磷 、 magnesium 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 2,6-bis(3,5-diethylbenzyl)pyridine
  参考文献：
  名称：

  伦敦溶液在二氯甲烷溶液中的分散度降低

  摘要：

  伦敦色散构成原子之间以及分子之间基本相互作用力之一。尽管已经开发出现代计算方法来恰当地描述气相中分散相互作用的强度，但是溶液中分子间和分子内分散的重要性仍有待充分理解，因为在这方面实验数据仍然很少。我们在本文中报告了伦敦分散体在气相和二氯甲烷溶液中对质子结合的二聚体的键解离的贡献的详细实验和计算研究，表明溶剂对分子间和分子内分散相互作用的衰减很大（约70％的二氯甲烷），但不完整，

  DOI：

  10.1021/jacs.7b06997
• 作为产物：
  描述：

  1,3,5-三乙基苯 在 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 lithium aluminium tetrahydride 、 jones reagent 、 溴 、 barium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 四氯化碳 、 水 、 丙酮 为溶剂， 生成 (3,5-diethylphenyl)methanol
  参考文献：
  名称：

  Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

  摘要：

  The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.(1) In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00445-9

文献信息

• [EN] IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK<br/>[FR] DÉRIVÉS D'IMIDAZOLIDINONE COMME INHIBITEURS DE PERK
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017046739A1

  公开（公告）日：2017-03-23

  The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及取代咪唑烷酮衍生物。具体而言，该发明涉及根据式I（I）中R1、R2、R3、R4、R5、R6、R7、X、Y1、Y2和Z所定义的化合物。该发明的化合物是PERK的抑制剂，可用于治疗癌症、癌前综合征、阿尔茨海默病、神经病性疼痛、脊髓损伤、创伤性脑损伤、缺血性中风、中风、帕金森病、糖尿病、代谢综合征、代谢紊乱、亨廷顿病、克雅氏病、致命性家族性失眠、格斯特曼-施特劳斯勒-谢因克症候群及相关朊蛋白病、肌萎缩侧索硬化、进行性核上性麻痹、心肌梗死、心血管疾病、炎症、器官纤维化、肝脏慢性和急性疾病、脂肪肝病、肝脂肪变性、肝纤维化、肺部慢性和急性疾病、肺纤维化、肾脏慢性和急性疾病、肾脏纤维化、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆症、额颞叶痴呆症、tau蛋白病、皮克氏病、尼曼-皮克氏病、淀粉样变性、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官移植用途中的运输。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制PERK活性和治疗相关疾病的方法。
• BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS
  申请人：Glick Gary D.

  公开号：US20090118244A1

  公开（公告）日：2009-05-07

  The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.

  本发明提供了一类苯二氮卓酮化合物及其药物组合物。本发明还提供了治疗某些皮肤病症的方法，例如特应性皮炎、酒渣鼻或银屑病，通过给予苯二氮卓酮以及通过将角质细胞暴露于苯二氮卓酮来减少角质细胞增殖的方法。
• [EN] BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME<br/>[FR] COMPOSÉS DE BENZODIAZÉPINONE ET MÉTHODES DE TRAITEMENT LES UTILISANT
  申请人：UNIV MICHIGAN

  公开号：WO2011035124A1

  公开（公告）日：2011-03-24

  The invention provides 1,4-benzodiazepinone compounds, pharmaceutical compositions, and methods of treating autoimmune disorders, chronic inflammatory disorders, and hyperproliferative disorders. For example, the 1,4-benzodiazepinone compounds and pharmaceutical compositions are contemplated to be useful for treating rheumatoid arthritis, graft-versus-host disease, inflammatory bowel disease, and the like.

  该发明提供了1,4-苯并二氮杂酮化合物、药物组合物以及治疗自身免疫性疾病、慢性炎症性疾病和过度增殖性疾病的方法。例如，这些1,4-苯并二氮杂酮化合物和药物组合物被认为对治疗类风湿关节炎、移植物抗宿主病、炎症性肠病等疾病有用。
• Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040072840A1

  公开（公告）日：2004-04-15

  The invention relates to the compounds of formula: 1 as well as to the salts thereof with inorganic or organic acids, to solvates thereof and/or to hydrates thereof, which have strong affinity and high selectivity for the human NK 1 receptors of substance P. The invention also relates to the process for preparing them, to the intermediate compounds of formula (VII) which are useful for the preparation, to pharmaceutical compositions containing them and to their fuse for the manufacture of medicinal products intended for treating any pathology in which substance P and the human NK 1 receptors are involved.

  本发明涉及公式1的化合物，以及其与无机或有机酸的盐，其溶剂化物和/或水合物，其具有强烈的亲和力和高选择性，可作用于物质P的人类NK1受体。本发明还涉及其制备过程，公式（VII）的中间体化合物对制备有用，含有它们的制药组合物，以及它们用于制造治疗任何涉及物质P和人类NK1受体的病理的药物的融合物。
• Benzodiazepinone compounds useful in the treatment of skin conditions
  申请人：The Regents of the University of Michigan

  公开号：US08188072B2

  公开（公告）日：2012-05-29

  The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.

  本发明提供了一系列苯二氮平酮化合物及其药物组成物。本发明还提供了通过给予苯二氮平酮来治疗某些皮肤病，例如特应性皮炎、酒渣鼻或银屑病的方法，以及通过将这些细胞暴露在苯二氮平酮下来减少角质细胞增殖的方法。